李昌

研究方向

1. 新型病毒载体

2. 针对艾滋病、遗传性血液病的体内基因治疗

教育及工作经历

2007 湖南农业大学，生物学，理学学士

2015 中国科学院大学，病毒学，理学博士

2015-2016 美国University of Maryland，Research Associate

2016-2019 美国University of Washington，Senior Fellow

2020-2022美国University of Washington，Acting Instructor

2022-2025美国University of Washington，Research   Assistant Professor

2025- 中国科学院武汉病毒研究所，研究员

近五年承担项目

国家高层次人才青年项目，在研，主持

近五年代表性论文

1.Li C*, Georgakopoulou A, Paschoudi K, Anderson AK, Huang L, Gil S, Giannaki M, Vlachaki E, Newby GA, Liu DR, Yannaki E, Kiem HP, Lieber A. (2024) Introducing a hemoglobin G-Makassar variant in HSCs by in vivo base editing treats sickle cell disease in mice. Mol Ther. 32(12):4353-4371. (* corresponding author)

Commented by Yao J and Shayakhmetov DM. (2024) Improving efficacy of in vivo therapy of sickle cell disease by hijacking natural biology of hematopoietic stem cells. Mol Ther. 2024 Dec 4;32(12):4167-4169.

2.Georgakopoulou A#, Li C#, Kiem HP, Lieber A. (2024) In vitro and in vivo expansion of CD33/HBG promoter-edited HSPCs with Mylotarg. Mol Ther Methods Clin Dev. 32(4):101343. doi: 10.1016/j.omtm.2024.101343. (# equal contribution)

3.Li C*, Anderson AK, Ruminski P, Rettig M, Karpova D, Kiem HP, DiPersio JF, Lieber A. (2024) A simplified, G-CSF-free procedure allows for in vivo HSC gene therapy of sickle cell disease in a mouse model. Blood Adv. 8(15):4089-4101. (* corresponding author)

4.Li C*, Anderson AK, Wang H, Gil S, Kim J, Huang L, Germond A, Baldessari A, Nelson VL, Peterson CW, Bui J, Kiem HP, Lieber A*. (2023) Stable expression of an HIV decoy receptor after in vivo HSC transduction in mice and NHPs: Safety and efficacy in protection from SHIV. Mol Ther. 31(4):1059-1073. (* corresponding authors)

5.Li C*, Georgakopoulou A, Newby GA, Chen PJ, Everette KA, Paschoudi K, Vlachaki E, Gil S, Anderson AK, Koob T, Huang L, Wang H,  Kiem HP, Liu DR, Yannaki E, Lieber A. In vivo HSC prime editing rescues Sickle Cell Disease in a mouse model. Blood. 141(17):2085-2099. (Cover story) (* corresponding author)

Commented by Sweeney CL, De Ravin SS. (2023) The promise of in vivo HSC prime editing. Blood. 141(17):2039-2040.

6.Li C*, Georgakopoulou A, Newby GA, Everette KA, Nizamis E, Paschoudi K, Vlachaki E, Gil S, Anderson AK, Koob T, Huang L, Wang H,  Kiem HP, Liu DR, Yannaki E, Lieber A*. In vivo base editing by a single intravenous vector injection for treatment of hemoglobinopathies. JCI insight. 2022;7(19):e162939. (* corresponding authors)

7.Li C, Wang H, Gil S, Germond A, Fountain C, Baldessari A, Kim J, Liu Z, Georgakopoulou A, Radtke S, Raskó T, Pande A, Chiang C, Chin E, Yannaki E, Izsvak Z, Papayannopoulou T, Kiem HP, Lieber A. Safe and efficient in vivo hematopoietic stem cell transduction in nonhuman primates using HDAd5/35++ vectors. Mol Ther Methods Clin Dev. 24:127-141.

8.Psatha N, Georgakopoulou A, Li C, Nandakumar V, Georgolopoulos G, Acosta R, Paschoudi K, Nelson J, Chee DR, Athanasiadou A, Kouvatsi A, Funnell A, Lieber A, Yannaki E, Papayannopoulou T. (2021) Enhanced HbF reactivation by multiplex mutagenesis of thalassemic CD34+ cells in vitro and in vivo. Blood. 138(17):1540-1553.

9.Li C, Goncalves KA, Raskó T, Pande A, Gil S, Liu Z, Izsvák Z, Papayannopoulou T, Davis JC, Kiem HP, Lieber A. (2021) Single-dose MGTA-145/plerixafor results in efficient mobilization and in vivo transduction of HSCs in mice. Blood Adv. 5(5): 1239–1249. 

10.Li C*, Georgakopoulou A, Mishra A, Gil S, Hawkins RD, Yannaki E, Lieber A. (2021) In vivo HSPC gene therapy with base editors allows for efficient reactivation of fetal γ-globin in β-YAC mice. (*corresponding author) Blood Adv. 5(4):1122-1135. 

11.Li C, Wang H, Georgakopoulou A, Gil S, Yannaki E, Lieber A. (2021) In vivo HSC gene therapy using a bi-modular HDAd5/35++ vector cures Sickle Cell Disease in a mouse model.Mol Ther. 29(2):822-837. 

Commented by Townes TA. (2021) A ‘Shot in the Arm’ for Sickle Cell Disease. Mol Ther. 29(2):416-417.